SLC1A5 and cancer: Importantly, gene silencing of SLC1A5 or its pharmacological inhibition reverted the resistant phenotype, thereby suggesting that SLC1A5 could be a promising diagnostic marker as well as a therapeutic target for TKI resistant cancers.